Biosidus

Executive Summary

Biosidus is an Argentine biotechnology company with over 40 years of experience in developing, manufacturing, and marketing biosimilar medicines for emerging markets. Leveraging a proprietary recombinant protein platform, the company produces cost-effective biologics across oncology, rheumatology, endocrinology, and immunology. As a commercial-stage private firm, Biosidus has raised approximately $50 million and serves patients primarily in Latin America. Its vertically integrated operations and patient-support programs position it as a key player in expanding access to biologic therapies in regions where affordability is critical. The company’s long-standing presence and technical expertise provide a solid foundation for sustained growth, though limited public disclosures and reliance on emerging-market dynamics introduce some uncertainty. Biosidus’s strategy focuses on capturing market share in biosimilar segments with high unmet need, supported by its established manufacturing capabilities and regulatory know-how in multiple countries. Looking ahead, the company is well-positioned to benefit from the increasing global demand for affordable biologics, particularly as patent expiries on reference products create opportunities for biosimilar competition in Latin America and other emerging markets.

Upcoming Catalysts (preview)

• 2027ANMAT approval and launch of a new oncology biosimilar (e.g., trastuzumab or rituximab) in Argentina60% success
• Q4 2026Expansion into a major Latin American market via distribution partnership (e.g., Brazil or Mexico)70% success
• 2027Potential funding round or strategic investment to scale biosimilar pipeline50% success